{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:42:51Z","timestamp":1792201371563,"version":"4.4.0"},"reference-count":78,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"DOI":"10.1007\/s12094-026-04565-5","type":"journal-article","created":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T19:02:16Z","timestamp":1792177336000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Value and research advances of ctDNA in perioperative therapy for non-small cell lung cancer"],"prefix":"10.1007","author":[{"given":"Jie","family":"Diao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqiong","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5981-7160","authenticated-orcid":false,"given":"Hong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,16]]},"reference":[{"key":"4565_CR1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2023.104080","volume":"190","author":"C Grant","year":"2023","unstructured":"Grant C, Hagopian G, Nagasaka M. Neoadjuvant therapy in non-small cell lung cancer. Crit Rev Oncol Hematol. 2023;190:1\u20138.","journal-title":"Crit Rev Oncol Hematol"},{"key":"4565_CR2","first-page":"1","volume":"577","author":"CS Li","year":"2023","unstructured":"Li CS, Shao J, Li PY. Circulating tumor DNA as liquid biopsy in lung cancer: biological characteristics and clinical integration. Cancer Lett. 2023;577:1\u201313.","journal-title":"Cancer Lett"},{"issue":"11","key":"4565_CR3","first-page":"2094","volume":"62","author":"QL Hu","year":"2023","unstructured":"Hu QL, Chen LJ, Li KR. Circulating tumor DNA: current implementation issues and future challenges for clinical utility. Clin Chem Lab Med. 2023;62(11):2094\u2013110.","journal-title":"Clin Chem Lab Med"},{"issue":"12","key":"4565_CR4","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1080\/14737159.2023.2268008","volume":"23","author":"N Raei","year":"2023","unstructured":"Raei N, Safaralizadeh R, Latifi-Navid S. Clinical application of circulating tumor DNA in metastatic cancers. Expert Rev Mol Diagn. 2023;23(12):1209\u201320.","journal-title":"Expert Rev Mol Diagn"},{"issue":"7655","key":"4565_CR5","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature22364","volume":"545","author":"C Abbosh","year":"2017","unstructured":"Abbosh C, Birkbak NJ, Wilson GA, Jamal-Hanjani M, Constantin T, Salari R, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446\u201351.","journal-title":"Nature"},{"issue":"10","key":"4565_CR6","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1002\/1878-0261.13178","volume":"16","author":"EL Symonds","year":"2022","unstructured":"Symonds EL, Pedersen SK, Yeo B, Al Naji H, Byrne SE, Roy A, et al. Assessment of tumor burden and response to therapy in patients with colorectal cancer using a quantitative ctDNA test for methylated BCAT1\/IKZF1. Mol Oncol. 2022;16(10):2031\u201341.","journal-title":"Mol Oncol"},{"issue":"7957","key":"4565_CR7","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/s41586-023-05776-4","volume":"616","author":"C Abbosh","year":"2023","unstructured":"Abbosh C, Frankell AM, Harrison T, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616(7957):553\u201362.","journal-title":"Nature"},{"issue":"7","key":"4565_CR8","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1001\/jamaoncol.2024.1779","volume":"10","author":"S Dong","year":"2024","unstructured":"Dong S, Wang Z, Zhang JT, et al. Circulating tumor DNA-guided de-escalation targeted therapy for advanced non-small cell lung cancer: a nonrandomized controlled trial. JAMA Oncol. 2024;10(7):932\u201340.","journal-title":"JAMA Oncol"},{"issue":"10","key":"4565_CR9","first-page":"1","volume":"129","author":"A Marinello","year":"2024","unstructured":"Marinello A, Tagliamento M, Pagliaro A, et al. Circulating tumor DNA to guide diagnosis and treatment of localized and locally advanced non-small cell lung cancer. Cancer Treat Rev. 2024;129(10):1\u201310.","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"4565_CR10","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.trecan.2024.04.004","volume":"10","author":"C Abbosh","year":"2024","unstructured":"Abbosh C, Hodgson D, Doherty GJ, et al. Implementing circulating tumor DNA as a prognostic biomarker in resectable non-small cell lung cancer. Trends Cancer. 2024;10(7):643\u201354.","journal-title":"Trends Cancer"},{"issue":"1","key":"4565_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00432-023-05550-z","volume":"150","author":"J Lu","year":"2024","unstructured":"Lu J, Feng Y, Guo K, Sun L, Ruan S, Zhang K. Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2024;150(1):25.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"21","key":"4565_CR12","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, Provencio M, Mitsudomi T, Awad MM, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973\u201385.","journal-title":"N Engl J Med"},{"issue":"3","key":"4565_CR13","first-page":"1","volume":"40","author":"FR Mohamed","year":"2024","unstructured":"Mohamed FR, Rose A, Sheehan-Hennessy L, et al. A blood test measuring DNA methylation of BCAT1 and IKZF1 for detection of lung adenocarcinoma. Cancer Treatment Research Communications. 2024;40(3):1\u201310.","journal-title":"Cancer Treatment Research Communications"},{"issue":"1","key":"4565_CR14","first-page":"1","volume":"594","author":"Y Boss\u00e9","year":"2024","unstructured":"Boss\u00e9 Y, Dasgupta A, Abadier M, et al. Prognostic implication of methylation-based circulating tumor DNA detection prior to surgery in stage I non-small cell lung cancer. Cancer Lett. 2024;594(1):1\u201310.","journal-title":"Cancer Lett"},{"issue":"9","key":"4565_CR15","doi-asserted-by":"crossref","DOI":"10.1093\/oncolo\/oyaf204","volume":"30","author":"AR de Abreu","year":"2025","unstructured":"de Abreu AR, Wyninckx A, Vandamme T, Op de Beeck K, Van Camp G, Peeters M, et al. Circulating tumor DNA detection in cancer: a comprehensive overview of current detection methods and prospects. Oncologist. 2025;30(9):oyaf204.","journal-title":"Oncologist"},{"issue":"1","key":"4565_CR16","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12672-025-01826-7","volume":"16","author":"G Passarella","year":"2025","unstructured":"Passarella G, Canova S, Abbate MI, Caspani G, Sala L, Russo A, et al. The hype around ctDNA guiding an informed perioperative therapeutic strategy in early-stage non-small cell lung cancer. Discov Oncol. 2025;16(1):100.","journal-title":"Discov Oncol"},{"issue":"18","key":"4565_CR17","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1056\/NEJMoa2304875","volume":"389","author":"JV Heymach","year":"2023","unstructured":"Heymach JV, Harpole D, Mitsudomi T, Taube JM, Galffy G, Hochmair M, et al. Perioperative durvalumab for resectable non-small-cell lung cancer. N Engl J Med. 2023;389(18):1672\u201384.","journal-title":"N Engl J Med"},{"issue":"25","key":"4565_CR18","doi-asserted-by":"crossref","first-page":"2924","DOI":"10.1200\/JCO.21.02660","volume":"40","author":"M Provencio","year":"2022","unstructured":"Provencio M, Serna-Blasco R, Nadal E, Insa A, Garc\u00eda-Campelo MR, Casal Rubio J, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40(25):2924\u201333.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4565_CR19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.pccm.2023.04.001","volume":"1","author":"LB Tang","year":"2023","unstructured":"Tang LB, Li RY, Wen HH, et al. Circulating tumor DNA (ctDNA)-based minimal residual disease in non-small cell lung cancer. Chinese Medical Journal Pulmonary and Critical Care Medicine. 2023;1(4):207\u201314.","journal-title":"Chinese Medical Journal Pulmonary and Critical Care Medicine"},{"issue":"10","key":"4565_CR20","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","volume":"41","author":"KZ Chen","year":"2023","unstructured":"Chen KZ, Yang F, Shen HF, et al. Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer. Cancer Cell. 2023;41(10):1749\u201362.","journal-title":"Cancer Cell"},{"key":"4565_CR21","doi-asserted-by":"crossref","first-page":"8009","DOI":"10.1200\/JCO.2025.43.16_suppl.8009","volume":"43","author":"M Reck","year":"2025","unstructured":"Reck M, et al. Association of post-surgical MRD status with neoadjuvant ctDNA dynamics, genomic mutations, and clinical outcomes in patients with resectable NSCLC (R-NSCLC) from the phase 3 AEGEAN trial. J Clin Oncol. 2025;43:8009.","journal-title":"J Clin Oncol"},{"issue":"4","key":"4565_CR22","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1158\/1078-0432.CCR-25-2958","volume":"32","author":"M Provencio","year":"2026","unstructured":"Provencio M, Serna-Blasco R, Nadal E, Gonz\u00e1lez Larriba JL, Mart\u00ednez-Mart\u00ed A, Bernab\u00e9 Caro R, et al. Minimal residual disease enhances prognostic stratification beyond pathologic response in resectable non-small cell lung cancer. Clin Cancer Res. 2026;32(4):748\u201355.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"4565_CR23","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/s41416-025-03047-9","volume":"133","author":"Z Zhang","year":"2025","unstructured":"Zhang Z, Jin X, Yin Q, Li P, Sun Z, Li W, et al. Cyst fluid ctDNA as a biomarker for genetic profiling and treatment monitoring in cystic brain metastases. Br J Cancer. 2025;133(3):325\u201336.","journal-title":"Br J Cancer"},{"issue":"1","key":"4565_CR24","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1158\/2767-9764.CRC-24-0234","volume":"6","author":"PH Lin","year":"2026","unstructured":"Lin PH, Tsai LW, Lo C, Kuo SH, Ni CC, Yu CH, et al. CtDNA detected after neoadjuvant therapy for HER2-positive breast cancer is associated with inferior outcomes and may inform adjuvant therapy. Cancer Res Commun. 2026;6(1):105\u201314.","journal-title":"Cancer Res Commun"},{"issue":"7","key":"4565_CR25","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1093\/jnci\/djaf061","volume":"117","author":"L Xia","year":"2025","unstructured":"Xia L, Pu Q, Kang R, Mei J, Li L, Yang Y, et al. Dynamic ctDNA informs whole-course postoperative precise management of NSCLC (LUNGCA study). J Natl Cancer Inst. 2025;117(7):1474\u201384.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"4565_CR26","volume":"10","author":"S Lei","year":"2026","unstructured":"Lei S, Yang Y, Jiang W, Xu H, Mao Y, Wang Y. Potential of minimal residual disease in guiding adjuvant therapy decisions in non-small cell lung cancer. JCO Precis Oncol. 2026;10(5):e2500977.","journal-title":"JCO Precis Oncol"},{"issue":"8","key":"4565_CR27","volume":"21","author":"AC Tan","year":"2026","unstructured":"Tan AC, Liao BC, Li M, Lee D, Uehara Y, Thamlikitkul L, et al. Consensus statement on ctDNA minimal residual disease testing in early stage NSCLC: a Delphi study by the Asian Thoracic Oncology Research Group. J Thorac Oncol. 2026;21(8):103696.","journal-title":"J Thorac Oncol"},{"key":"4565_CR28","doi-asserted-by":"crossref","unstructured":"Zhang, J. T., Chen, K. Z., Gao, X., Huang, C., Cui, Q., Kong, J., Zhang, Y. C., Jiao, Z., Yin, R., Li, Z. M., Zhou, Z. Z., Li, Z. F., Yuan, X. Q., Liu, S. M., Gao, W., Gong, Y., Du, X., Zheng, M. M., Yan, H. H., ... Wu, Y. L. (2026). LAMPAD: An integrated circulating tumor DNA-based model for predicting potential cure in patients with resected NSCLC.\u00a0Journal of Thoracic Oncology. Advance online publication.","DOI":"10.1016\/j.jtho.2026.103729"},{"key":"4565_CR29","doi-asserted-by":"crossref","unstructured":"Wang, B. X., Jiang, H., Ou, W., et al. (2026). Perioperative ctDNA dynamics predict outcomes in resectable NSCLC using an ultrasensitive and cost-effective assay.\u00a0npj Precision Oncology. Advance online publication.","DOI":"10.1038\/s41698-026-01621-9"},{"issue":"7","key":"4565_CR30","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/2159-8290.CD-21-1486","volume":"12","author":"JT Zhang","year":"2022","unstructured":"Zhang JT, Liu SY, Gao W, Liu SM, Yan HH, Ji L, et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer. Cancer Discov. 2022;12(7):1690\u2013701.","journal-title":"Cancer Discov"},{"issue":"5","key":"4565_CR31","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/10408363.2024.2302116","volume":"61","author":"A Ntzifa","year":"2024","unstructured":"Ntzifa A, Marras T, Georgoulias V, Lianidou E. Liquid biopsy for the management of NSCLC patients under osimertinib treatment. Crit Rev Clin Lab Sci. 2024;61(5):347\u201369.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"4565_CR32","doi-asserted-by":"crossref","unstructured":"Cui, Q., Zhang, J. T., Yin, H., Zhang, K. P., Xu, J., Xu, F. P., Zhong, W. Z., Wu, Y. L., & Zhang, Q. L. (2026). Comparison of circulating tumor DNA assays for molecular residual disease detection in non-small cell lung cancer.\u00a0Journal of Thoracic Oncology. Advance online publication.","DOI":"10.1016\/j.jtho.2026.104090"},{"issue":"6","key":"4565_CR33","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1200\/JCO.21.01929","volume":"40","author":"B Pellini","year":"2022","unstructured":"Pellini B, Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent. J Clin Oncol. 2022;40(6):567\u201375.","journal-title":"J Clin Oncol"},{"issue":"15","key":"4565_CR34","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1158\/1078-0432.CCR-21-3044","volume":"28","author":"L Xia","year":"2022","unstructured":"Xia L, Mei J, Kang R, Deng S, Chen Y, Yang Y, et al. Perioperative ctDNA-based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1). Clin Cancer Res. 2022;28(15):3308\u201317.","journal-title":"Clin Cancer Res"},{"issue":"5","key":"4565_CR35","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s40291-024-00725-x","volume":"28","author":"C Chen","year":"2024","unstructured":"Chen C, Douglas MP, Ragavan MV, et al. Clinical validity and utility of circulating tumor DNA (ctDNA) testing in advanced non-small cell lung cancer (aNSCLC): a systematic literature review and meta-analysis. Mol Diagn Ther. 2024;28(5):525\u201336.","journal-title":"Mol Diagn Ther"},{"issue":"6","key":"4565_CR36","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1634\/theoncologist.2018-0433","volume":"24","author":"YK Chae","year":"2019","unstructured":"Chae YK, Davis AA, Agte S, et al. Clinical implications of circulating tumor DNA tumor mutational burden (ctDNA TMB) in non-small cell lung cancer. Oncologist. 2019;24(6):820\u20138.","journal-title":"Oncologist"},{"issue":"1","key":"4565_CR37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jtcvs.2025.09.017","volume":"171","author":"DR Jones","year":"2026","unstructured":"Jones DR, Opitz I, Harpole D, Yanagawa J, Lim E, Tsutani Y, et al. TROPION-Lung12: a phase 3 study of adjuvant datopotamab deruxtecan and rilvegostomig in ctDNA-positive or high-risk pathology stage I non-small cell lung cancer. J Thorac Cardiovasc Surg. 2026;171(1):1\u20139.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"4565_CR38","volume":"6","author":"Y Sato","year":"2025","unstructured":"Sato Y. Liquid biopsy for minimal residual disease and monitoring in early-stage non-small cell lung cancer: current clinical utility and implementation challenges. Explor Med. 2025;6:1001349.","journal-title":"Explor Med"},{"issue":"12","key":"4565_CR39","doi-asserted-by":"crossref","first-page":"5491","DOI":"10.21037\/tlcr-2025-900","volume":"14","author":"X Chen","year":"2025","unstructured":"Chen X, Zhang M, Zhou Q, Guo N, Cao B, Zeng H, et al. Circulating tumor DNA as prognostic markers of non-small cell lung cancer (NSCLC): a systematic review and meta-analysis. Transl Lung Cancer Res. 2025;14(12):5491\u2013508.","journal-title":"Transl Lung Cancer Res"},{"issue":"7","key":"4565_CR40","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1158\/1078-0432.CCR-24-2909","volume":"31","author":"JT Zhang","year":"2025","unstructured":"Zhang JT, Liu SY, Gao X, Liu SM, Yan B, Huang C, et al. Follow-up analysis enhances understanding of molecular residual disease in localized non-small cell lung cancer. Clin Cancer Res. 2025;31(7):1305\u201314.","journal-title":"Clin Cancer Res"},{"issue":"12","key":"4565_CR41","volume":"6","author":"L Liu","year":"2025","unstructured":"Liu L, Liang W, Cao W, Wang H, Liang H, Huang L, et al. Personalized and tumor informed circulating tumor DNA assay for molecular residual disease monitoring of solid malignancies. MedComm. 2025;6(12):e70483.","journal-title":"MedComm"},{"issue":"10","key":"4565_CR42","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1016\/j.ccell.2023.08.010","volume":"41","author":"K Chen","year":"2023","unstructured":"Chen K, Yang F, Shen H, Wang C, Li X, Chervova O, et al. Individualized tumor-informed circulating tumor DNA analysis for postoperative monitoring of non-small cell lung cancer. Cancer Cell. 2023;41(10):1749-1762.e6.","journal-title":"Cancer Cell"},{"issue":"3","key":"4565_CR43","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.21037\/tlcr-24-942","volume":"14","author":"Y Wang","year":"2025","unstructured":"Wang Y, Shao W, Li H, Zhao P, Tian L, Zhang L, et al. Clinical application of minimal residual disease detection by ctDNA testing in non-small cell lung cancer: a narrative review. Transl Lung Cancer Res. 2025;14(3):1007\u201320.","journal-title":"Transl Lung Cancer Res"},{"issue":"3","key":"4565_CR44","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1515\/jtim-2026-0023","volume":"14","author":"Yuan, X., Jin, R., Wei, Y., He, Y., Weng, L., Li, Z., Wang, J. A., Li, X., Xu, J., Bai, J., Wang, Y., Zhang, Q., Zhou, N., Hou, Y., Wang, G., Zhang, J., Yin, R., Li, Z., Li, Y., \u2026 Chen, K., & REMODEL Study","year":"2026","unstructured":"Yuan, X., Jin, R., Wei, Y., He, Y., Weng, L., Li, Z., Wang, J. A., Li, X., Xu, J., Bai, J., Wang, Y., Zhang, Q., Zhou, N., Hou, Y., Wang, G., Zhang, J., Yin, R., Li, Z., Li, Y., \u2026 Chen, K., & REMODEL Study. Molecular residual disease-based novel modality of postoperative management for non-small-cell lung cancer (REMODEL): Protocol for a prospective multicenter study. Journal of Translational Internal Medicine. 2026;14(3):470\u201380.","journal-title":"Journal of Translational Internal Medicine"},{"issue":"13","key":"4565_CR45","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/1759-7714.15281","volume":"15","author":"Y Oh","year":"2024","unstructured":"Oh Y, Yoon SM, Lee J, Park JH, Lee S, Hong T, et al. Personalized, tumor-informed, circulating tumor DNA assay for detecting minimal residual disease in non-small cell lung cancer patients receiving curative treatments. Thorac Cancer. 2024;15(13):1095\u2013102.","journal-title":"Thorac Cancer"},{"issue":"6","key":"4565_CR46","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1007\/s12094-025-04182-8","volume":"28","author":"AU Khan","year":"2026","unstructured":"Khan AU, Avazmetova I, Ruzieva M, Matchanova B, Dauletbaev A, Bilalov E, et al. Prognostic value of postoperative circulating tumor DNA for recurrence-free survival in resected non-small cell lung cancer: a systematic review and meta-analysis. Clin Transl Oncol. 2026;28(6):2086\u201398.","journal-title":"Clin Transl Oncol"},{"issue":"1","key":"4565_CR47","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/cac2.12505","volume":"44","author":"D Miao","year":"2024","unstructured":"Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, et al. Management of locally advanced non-small cell lung cancer: state of the art and future directions. Cancer Commun. 2024;44(1):23\u201346.","journal-title":"Cancer Commun"},{"issue":"4","key":"4565_CR48","doi-asserted-by":"crossref","DOI":"10.1093\/jncics\/pkad040","volume":"7","author":"A Mittal","year":"2023","unstructured":"Mittal A, Molto Valiente C, Tamimi F, Di Iorio M, Al-Showbaki L, Cescon DW, et al. Utility of ctDNA in predicting relapse in solid tumors after curative therapy: a meta-analysis. JNCI Cancer Spectr. 2023;7(4):pkad040.","journal-title":"JNCI Cancer Spectr"},{"issue":"1","key":"4565_CR49","volume":"9","author":"AE Boukouris","year":"2025","unstructured":"Boukouris AE, Michaelidou K, Joosse SA, Charpidou A, Mavroudis D, Syrigos KN, et al. A comprehensive overview of minimal residual disease in the management of early-stage and locally advanced non-small cell lung cancer. npj Precis Oncol. 2025;9(1):178.","journal-title":"npj Precis Oncol"},{"issue":"8","key":"4565_CR50","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.annonc.2022.05.520","volume":"33","author":"J Pascual","year":"2022","unstructured":"Pascual J, Attard G, Bidard FC, Curigliano G, De Mattos-Arruda L, Diehn M, et al. ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2022;33(8):750\u201368.","journal-title":"Ann Oncol"},{"issue":"5","key":"4565_CR51","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3892\/or.2023.8543","volume":"49","author":"H Chen","year":"2023","unstructured":"Chen H, Zhou Q. Detecting liquid remnants of solid tumors treated with curative intent: circulating tumor DNA as a biomarker of minimal residual disease (review). Oncol Rep. 2023;49(5):106.","journal-title":"Oncol Rep"},{"issue":"1","key":"4565_CR52","volume":"7","author":"HVA Nguyen","year":"2025","unstructured":"Nguyen HVA, Nguyen N, Nguyen T, Nguyen DS, Nguyen HN, Tu LN. Direct comparison of tumor-informed and tumor-naive circulating tumor DNA assays for recurrence detection in early-stage NSCLC. JTO Clin Res Rep. 2025;7(1):100927.","journal-title":"JTO Clin Res Rep"},{"issue":"1","key":"4565_CR53","volume":"5","author":"B Jimenez-Munarriz","year":"2026","unstructured":"Jimenez-Munarriz B, Urtecho B, Rabey MR, Leighl NB. Circulating-tumour DNA (ctDNA) in NSCLC: mechanisms, evidence and the future of MRD detection. BMJ Oncol. 2026;5(1):e001002.","journal-title":"BMJ Oncol"},{"issue":"12","key":"4565_CR54","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1038\/s41587-021-00981-w","volume":"39","author":"DM Kurtz","year":"2021","unstructured":"Kurtz DM, Soo J, Co Ting Keh L, Alig S, Chabon JJ, Sworder BJ, et al. Enhanced detection of minimal residual disease by targeted sequencing of phased variants in circulating tumor DNA. Nat Biotechnol. 2021;39(12):1537\u201347.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"4565_CR55","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006284","volume":"11","author":"NP Semenkovich","year":"2023","unstructured":"Semenkovich NP, Szymanski JJ, Earland N, Chauhan PS, Pellini B, Chaudhuri AA. Genomic approaches to cancer and minimal residual disease detection using circulating tumor DNA. J Immunother Cancer. 2023;11(6):e006284.","journal-title":"J Immunother Cancer"},{"key":"4565_CR56","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-3375","author":"JM Isbell","year":"2023","unstructured":"Isbell JM, Li BT, Razavi P, Reis-Filo J, Liu S, Selenica P, et al. Abstract 3375: ultrasensitive ctDNA minimal residual disease monitoring in early NSCLC with PhasED-Seq. Cancer Res. 2023. https:\/\/doi.org\/10.1158\/1538-7445.am2023-3375.","journal-title":"Cancer Res"},{"issue":"4","key":"4565_CR57","doi-asserted-by":"crossref","first-page":"237","DOI":"10.62347\/EBRY4326","volume":"14","author":"W Dong","year":"2025","unstructured":"Dong W, Hu W, Lu Y, Zheng Q. Cell-free DNA fragmentomics: a universal framework for early cancer detection and monitoring. Am J Clin Exp Immunol. 2025;14(4):237\u201340.","journal-title":"Am J Clin Exp Immunol"},{"key":"4565_CR58","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2021.671057","volume":"12","author":"ME Barefoot","year":"2021","unstructured":"Barefoot ME, Loyfer N, Kiliti AJ, McDeed AP IV, Kaplan T, Wellstein A. Detection of cell types contributing to cancer from circulating, cell-free methylated DNA. Front Genet. 2021;12:671057.","journal-title":"Front Genet"},{"issue":"12","key":"4565_CR59","first-page":"1493","volume":"22","author":"J Xu","year":"2025","unstructured":"Xu J, Fang K, Li X, Han L, Sun S, Sun T. From residual risk to precision intervention: the evolving role of minimal residual disease in breast cancer management. Cancer Biol Med. 2025;22(12):1493\u2013514.","journal-title":"Cancer Biol Med"},{"issue":"11","key":"4565_CR60","volume":"5","author":"L Li","year":"2024","unstructured":"Li L, Sun Y. Circulating tumor DNA methylation detection as biomarker and its application in tumor liquid biopsy: advances and challenges. MedComm. 2024;5(11):e766.","journal-title":"MedComm"},{"issue":"2","key":"4565_CR61","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.3390\/ijms24021503","volume":"24","author":"T Qi","year":"2023","unstructured":"Qi T, Pan M, Shi H, Wang L, Bai Y, Ge Q. Cell-free DNA fragmentomics: the novel promising biomarker. Int J Mol Sci. 2023;24(2):1503.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4565_CR62","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1186\/s12915-023-01752-6","volume":"21","author":"D Zhu","year":"2023","unstructured":"Zhu D, Wang H, Wu W, Geng S, Zhong G, Li Y, et al. Circulating cell-free DNA fragmentation is a stepwise and conserved process linked to apoptosis. BMC Biol. 2023;21(1):253.","journal-title":"BMC Biol"},{"issue":"1","key":"4565_CR63","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-46435-0","volume":"15","author":"KE Stanley","year":"2024","unstructured":"Stanley KE, Jatsenko T, Tuveri S, Sudhakaran D, Lannoo L, Van Calsteren K, et al. Cell type signatures in cell-free DNA fragmentation profiles reveal disease biology. Nat Commun. 2024;15(1):2220.","journal-title":"Nat Commun"},{"issue":"7","key":"4565_CR64","volume":"7","author":"Y Xu","year":"2026","unstructured":"Xu Y, Bao H, Huang D, Zhang K, Zhu J, Yang L, et al. Toward generalizable prediction of cancer signal using a cell-free DNA language model. Cell Rep Med. 2026;7(7):102866.","journal-title":"Cell Rep Med"},{"issue":"466","key":"4565_CR65","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat4921","volume":"10","author":"F Mouliere","year":"2018","unstructured":"Mouliere F, Chandrananda D, Piskorz AM, Moore EK, Morris J, Ahlborn LB, et al. Enhanced detection of circulating tumor DNA by fragment size analysis. Sci Transl Med. 2018;10(466):eaat4921.","journal-title":"Sci Transl Med"},{"issue":"5","key":"4565_CR66","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2767-9764.CRC-22-0363","volume":"3","author":"S Wang","year":"2023","unstructured":"Wang S, Xia Z, You J, Gu X, Meng F, Chen P, et al. Enhanced detection of landmark minimal residual disease in lung cancer using cell-free DNA fragmentomics. Cancer Res Commun. 2023;3(5):933\u201342.","journal-title":"Cancer Res Commun"},{"issue":"14","key":"4565_CR67","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1002\/1878-0261.13267","volume":"16","author":"DCL Vessies","year":"2022","unstructured":"Vessies DCL, Schuurbiers MMF, van der Noort V, Schouten I, Linders TC, Lanfermeijer M, et al. Combining variant detection and fragment length analysis improves detection of minimal residual disease in postsurgery circulating tumour DNA of stage II-IIIA NSCLC patients. Mol Oncol. 2022;16(14):2719\u201332.","journal-title":"Mol Oncol"},{"issue":"1","key":"4565_CR68","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1186\/s13059-025-03607-5","volume":"26","author":"H Wang","year":"2025","unstructured":"Wang H, Mennea PD, Chan YKE, Cheng Z, Neofytou MC, Surani AA, et al. A standardized framework for robust fragmentomic feature extraction from cell-free DNA sequencing data. Genome Biol. 2025;26(1):141.","journal-title":"Genome Biol"},{"issue":"22","key":"4565_CR69","doi-asserted-by":"crossref","first-page":"3162","DOI":"10.1111\/1759-7714.14668","volume":"13","author":"J Zheng","year":"2022","unstructured":"Zheng J, Wang YB, Hu C, et al. Predictive value of early kinetics of ctDNA combined with cfDNA and serum CEA for EGFR-TKI treatment in advanced non-small cell lung cancer. Thorac Cancer. 2022;13(22):3162\u201373.","journal-title":"Thorac Cancer"},{"key":"4565_CR70","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.neo.2024.101006","volume":"53","author":"K Xiong","year":"2024","unstructured":"Xiong K, Yang Y, Yang YN, et al. Tumor marker-based Recist\u2122 is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutations. Neoplasia. 2024;53:1\u201311.","journal-title":"Neoplasia"},{"issue":"s1","key":"4565_CR71","doi-asserted-by":"crossref","first-page":"S283","DOI":"10.3233\/TUB-220044","volume":"46","author":"MJ Duffy","year":"2024","unstructured":"Duffy MJ. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: early detection, monitoring and therapy prediction. Tumour Biol. 2024;46(s1):S283\u201395.","journal-title":"Tumour Biol"},{"key":"4565_CR72","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.tranon.2023.101788","volume":"38","author":"P Vryza","year":"2023","unstructured":"Vryza P, Fischer T, Mistakidi E, et al. Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies. Transl Oncol. 2023;38:1\u201318.","journal-title":"Transl Oncol"},{"issue":"2","key":"4565_CR73","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/1759-7714.13741","volume":"12","author":"N Jiang","year":"2021","unstructured":"Jiang N, Zhou J, Zhang WH, et al. RNF213 gene mutation in circulating tumor DNA detected by targeted next-generation sequencing in the assisted discrimination of early-stage lung cancer from pulmonary nodules. Thorac Cancer. 2021;12(2):181\u201393.","journal-title":"Thorac Cancer"},{"issue":"12","key":"4565_CR74","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11864-021-00911-7","volume":"22","author":"A Pellerino","year":"2021","unstructured":"Pellerino A, Bruno F, Rud\u00e0 R, et al. Systemic therapy for lung cancer brain metastases. Curr Treat Options Oncol. 2021;22(12):1\u201323.","journal-title":"Curr Treat Options Oncol"},{"issue":"6","key":"4565_CR75","doi-asserted-by":"crossref","first-page":"605","DOI":"10.3343\/alm.2023.43.6.605","volume":"43","author":"SM Cho","year":"2023","unstructured":"Cho SM, Lee HS, Jeon S, et al. Cost-effectiveness analysis of three diagnostic strategies for the detection of EGFR mutation in advanced non-small cell lung cancer. Ann Lab Med. 2023;43(6):605\u201313.","journal-title":"Ann Lab Med"},{"issue":"9","key":"4565_CR76","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1038\/s41587-021-00857-z","volume":"39","author":"IW Deveson","year":"2021","unstructured":"Deveson IW, Gong B, Lai K, et al. Evaluating the analytical validity of circulating tumor DNA sequencing assays for precision oncology. Nat Biotechnol. 2021;39(9):1115\u201328.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"4565_CR77","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-024-63411-2","volume":"14","author":"M Kim","year":"2024","unstructured":"Kim M, Park J, Oh SH, et al. Deep learning model integrating cfDNA methylation and fragment size profiles for lung cancer diagnosis. Sci Rep. 2024;14(1):1\u201312.","journal-title":"Sci Rep"},{"issue":"5","key":"4565_CR78","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/1878-0261.13357","volume":"17","author":"J Wu","year":"2023","unstructured":"Wu J, Liu ZQ, Huang TX, et al. Cerebrospinal fluid circulating tumor DNA depicts profiling of brain metastasis in NSCLC. Mol Oncol. 2023;17(5):810\u201324.","journal-title":"Mol Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04565-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-026-04565-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:25:50Z","timestamp":1792200350000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12094-026-04565-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,16]]},"references-count":78,"alternative-id":["4565"],"URL":"https:\/\/doi.org\/10.1007\/s12094-026-04565-5","relation":{},"ISSN":["1699-3055"],"issn-type":[{"value":"1699-3055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,16]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors have approved the manuscript and agree to its publication if accepted.","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}